IKT

1.3201.54%
TM

Ted M. Dawson

Member of Scientific Advisory Board

Dr. Ted M. Dawson, M.D., Ph.D., is Co-Founder and Director of Valted Seq, Inc. He is a Member of Scientific Advisory Board of Inhibikase Therapeutics, Inc. He serves as Member of Scientific Advisory Board at Ventyx Biosciences, Inc. from 2025. and served as its Science Advisor. Dr. Dawson focuses on movement disorders with many advances in neurobiology of disease that have stemmed from Dr. Dawson’s identification of the mechanisms of neuronal cell death and the elucidation of the molecular mechanisms of neurodegeneration. He pioneered the role of nitric oxide in neuronal injury in stroke and excitotoxicity and elucidated the molecular mechanisms by which nitric oxide and poly (ADP-ribose) polymerase kill neurons. His studies of nitric oxide led to major insights into the neurotransmitter functions of this gaseous messenger molecule. He co-discovered the neurotrophic properties of non-immunosuppressant immunophilin ligands. Dr. Dawson’s discoveries have led to innovative approaches and enhanced the development of new agents to treat neurologic disorders, such as Parkinson’s disease and Alzheimer’s disease as well as other neurodegenerative disorders. Dr. Dawson received his medical degree and Doctor of Philosophy in pharmacology from the University of Utah School of Medicine. He then completed an internship in medicine at the University of Utah Affiliated Hospitals before going to the Hospital of the University of Pennsylvania for a neurology residency. Next, he came to The Johns Hopkins where he completed a fellowship in neuroscience and senior clinical fellowship in movement disorders.

Positions